RO 7009789

Drug Profile

RO 7009789

Alternative Names: RG-7876; RO-7009789

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Abramson Cancer Center of the University of Pennsylvania; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Dec 2015 Roche initiates enrolment in a phase I trial for Solid tumours (Combination therapy; Late-stage disease; Second-line therapy or greater) in Canada, Denmark and Spain (NCT02665416)
  • 01 Oct 2015 Phase-I clinical trials in Pancreatic cancer in USA (IV) (NCT02588443)
  • 01 Dec 2014 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain after December 2014 (IV and SC) (NCT02304393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top